Auriant Mining AB (publ.) publishes Q4 2022 Interim Report (January - December)
Highlights 12 months 2022
Amounts in parentheses refer to the same period in the previous year.
- Gold production 780 kg /25,082 oz (911 kg /29,283 oz).
- Gold sales 882 kg /28,364 oz (819 kg /26,316 oz)
- Consolidated revenue US$ 51.1 mln (US$ 47.7 mln)
- Net profit after tax US$ 7.6 mln (US$ 7.1 mln)
- EBITDA US$ 15.4 mln (US$ 22.5 mln)
- Net cash flow generated from operating activities US$ 12.3 mln (US$ 17.8 mln)
- Average selling price for gold US$ 1,800 per oz (US$ 1,812 per oz)
Significant events after the reporting period
In February 2023, the Group extended the repayment period of the existing VTB bank loan of US$ 7.6 mln from 01 February 2023 until the end of 2024. The currency of the bank loan was converted from USD into RUR with a new interest rate of central bank key rate (7.5%) plus a margin of 3.25%.
Full report is available here
For more information, please contact:
Danilo Lange, CEO
Tel: +7 495 109 02 82
E-mail: d.lange@auriant.com
Company name: Auriant Mining AB
Short name: AUR
ISIN-code: SE0001337213
Website: www.auriant.com
Auriant Mining AB (AUR) is a Swedish junior mining company focused on gold exploration and production in Russia, primarily in the Republic of Tyva, Zabaikalye and the Republic of Khakassia. The company has currently four assets, including two operating mines (Tardan and Alluvial at Staroverinskaya), one early stage exploration asset and one development asset.
Since July 19, 2010, Auriant Mining´s shares are traded on Nasdaq First North Premier Growth Market under the short name AUR. For more information, please visit www.auriant.com. G&W Fondkommission is Certified Adviser to Auriant, for more information please visit www.gwkapital.se.
This information is information that Auriant Mining AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.20 CET on February 28th, 2023.
Cautionary Statement: Statements and assumptions made in this report with respect to Auriant Mining AB’s (“AUR”) current plans, estimates, strategies and beliefs, and other statements that are not historical facts, are forward-looking statements about the future performance of AUR. Forward-looking statements include, but are not limited to, those using words such as "may", "might", "seeks", "expects", "anticipates", "estimates", "believes", "projects", "plans", strategy", "forecast" and similar expressions. These statements reflect management's expectations and assumptions in light of currently available information. They are subject to a number of risks and uncertainties, including, but not limited to, (i) changes in the economic, regulatory and political environments in the countries where AUR operates; (ii) changes relating to the geological information available in respect of the various projects undertaken; (iii) AUR’s continued ability to secure enough financing to carry on its operations as a going concern; (iv) the success of its potential joint ventures and alliances, if any; (v) exchange rates, particularly between the Russian rouble and the U.S. dollar. In the light of the many risks and uncertainties surrounding any gold production and exploration company at an early stage of its development, the actual results could differ materially from those presented and forecast in this report. AUR assumes no unconditional obligation to immediately update any such statements and/or forecasts.
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
CFO Martin Klöti to leave Schweiter Technologies29.3.2023 06:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR CFO Martin Klöti to leave Schweiter Technologies Martin Klöti, Chief Financial Officer (CFO) and member of the Management of Schweiter Technologies, has decided to leave the company Steinhausen, 29 March 2023 – Martin Klöti, who has been with Schweiter Technologies since 2003 and CFO of the Group since 2014, has decided to leave the Management as of September 2023 to take up a new position outside the company. The Board of Directors will be sorry to see him leave and wishes to take this opportunity to thank him for his many years of dedicated service and his enormous contribution to the development of Schweiter Technologies. The search for his successor will be initiated forthwith. For further information please contact: Martin Klöti, CFO Tel. +41 41 757 77 00 investor@schweiter.com ABOUT SCHWEITER Schweiter Technologies, with its head office in Steinhausen, Switzerland, is a globally active Group focusing on composites solutions with its divi
Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia29.3.2023 05:39:38 CEST | Press release
-- The two parties will collaborate to develop and commercialize toripalimab in 9 Southeast Asian countries through a joint venture company, Excellmab -- Excellmab will be responsible for the development, medical affairs, production of finished products, and commercialization of toripalimab within the cooperation territory. The profits available for distribution by Excellmab will be distributed in proportion to the respective shareholdings of the parties -- Using the Excellmab platform, the two parties also plan to collaborate extensively to introduce more high-quality innovative drugs into Southeast Asian markets to achieve joint and long-term development -- According to the progress of toripalimab’s R&D and other projects, Junshi Biosciences may receive a milestone payment of up to approximately US$4.52 million, plus a certain percentage of royalties on net sales SHANGHAI, China and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Bioscience
Aduro Clean Technologies Increases Size of Private Placement to $4 Million29.3.2023 02:12:40 CEST | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SARNIA, Ontario, March 28, 2023 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics, and to transform heavy crude and renewable oils into feedstocks and higher-value fuels, is pleased to announce that, further to its news release dated March 8, 2023, it has increased the size of its non-brokered private placement of units (the “Units”) at $0.93 per Unit for gross proceeds of a minimum of $1,999,965 and up to a maximum of $4,000,000 (the “LIFE Offering”). Each Unit will consist of one (1) common share in the capital of the Company (each, a “Common Share”) and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable into one (1) Common Share (each, a “Warrant Share”) at a price o
ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform28.3.2023 22:05:00 CEST | Press release
SOLANA BEACH, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance. “This invention will help clinicians guide the delivery of biologic therapies — from stem cell transplants to gene therapy vectors — to specific locations in the human brain with real-time image guidance,” said Dr. Daniel Lim, MD, PhD, Professor of Neurological Surgery at UCSF. “By helping surgeons tailor biologic delivery to individual patient anatomy and specific diseases, I hope that this invention can contribute importantly to the successful treatment of neurological disor
Development of the Annual General Meeting of the BANK of Greenland28.3.2023 22:03:19 CEST | Press release
Minutes of General Meeting To Nasdaq OMX Copenhagen 28 March 2022 Company announcement no. 05/2023 Development of the Annual General Meeting of the BANK of Greenland Today, the BANK of Greenland held its Annual General Meeting in accordance with the Articles of Association and the previously published notice convening the meeting. The Annual General Meeting was attended by shareholders representing 1,049,468 votes, of which 612,498 votes were given by proxy to the Board of Directors, 62,821 votes were covered by instructions to holders of power of attorney and 115,455 votes of correspondance. The Board of Directors' Report on the Bank's activities during the past year The Chairman of the Board of Directors Gunnar í Liða presented the Board of Directors' report on the Bank's activities during the past year. The report of the Board of Directors was noted. The Chairman's report can be viewed on the Bank's website at www.banken.gl. The minutes of the Annual General Meeting will also be pub